Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 5
2005 1
2007 1
2008 3
2009 3
2010 6
2011 1
2012 9
2013 12
2014 15
2015 19
2016 35
2017 51
2018 40
2019 64
2020 145
2021 223
2022 190
2023 58
2024 1

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 28986512

724 results

Results by year

Filters applied: . Clear all
Page 1
Cold Kit for Prostate-Specific Membrane Antigen (PSMA) PET Imaging: Phase 1 Study of 68Ga-Tris(Hydroxypyridinone)-PSMA PET/CT in Patients with Prostate Cancer.
Hofman MS, Eu P, Jackson P, Hong E, Binns D, Iravani A, Murphy D, Mitchell C, Siva S, Hicks RJ, Young JD, Blower PJ, Mullen GE. Hofman MS, et al. J Nucl Med. 2018 Apr;59(4):625-631. doi: 10.2967/jnumed.117.199554. Epub 2017 Oct 6. J Nucl Med. 2018. PMID: 28986512 Free PMC article. Clinical Trial.
PSA-stratified detection rates for [68Ga]THP-PSMA, a novel probe for rapid kit-based 68Ga-labeling and PET imaging, in patients with biochemical recurrence after primary therapy for prostate cancer.
Derlin T, Schmuck S, Juhl C, Zörgiebel J, Schneefeld SM, Walte ACA, Hueper K, von Klot CA, Henkenberens C, Christiansen H, Thackeray JT, Ross TL, Bengel FM. Derlin T, et al. Eur J Nucl Med Mol Imaging. 2018 Jun;45(6):913-922. doi: 10.1007/s00259-017-3924-9. Epub 2018 Jan 7. Eur J Nucl Med Mol Imaging. 2018. PMID: 29308527
The management impact of 68gallium-tris(hydroxypyridinone) prostate-specific membrane antigen (68Ga-THP-PSMA) PET-CT imaging for high-risk and biochemically recurrent prostate cancer.
Kulkarni M, Hughes S, Mallia A, Gibson V, Young J, Aggarwal A, Morris S, Challacombe B, Popert R, Brown C, Cathcart P, Dasgupta P, Warbey VS, Cook GJR. Kulkarni M, et al. Eur J Nucl Med Mol Imaging. 2020 Mar;47(3):674-686. doi: 10.1007/s00259-019-04643-7. Epub 2019 Dec 23. Eur J Nucl Med Mol Imaging. 2020. PMID: 31872280 Free PMC article.
68Ga-PSMA-HBED-CC PET/CT imaging in Black versus White South African patients with prostate carcinoma presenting with a low volume, androgen-dependent biochemical recurrence: a prospective study.
Lengana T, van de Wiele C, Lawal I, Maes A, Ebenhan T, Boshomane T, Zeevaart JR, Ankrah A, Mokgoro N, Vorster M, Sathekge M. Lengana T, et al. Nucl Med Commun. 2018 Feb;39(2):179-185. doi: 10.1097/MNM.0000000000000791. Nucl Med Commun. 2018. PMID: 29257006 Clinical Trial.
Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.
Morigi JJ, Stricker PD, van Leeuwen PJ, Tang R, Ho B, Nguyen Q, Hruby G, Fogarty G, Jagavkar R, Kneebone A, Hickey A, Fanti S, Tarlinton L, Emmett L. Morigi JJ, et al. J Nucl Med. 2015 Aug;56(8):1185-90. doi: 10.2967/jnumed.115.160382. Epub 2015 Jun 25. J Nucl Med. 2015. PMID: 26112024 Free article.
724 results